Company Overview
Tragara Pharmaceuticals is an oncology specialty pharmaceutical
company focusing its development efforts on three NCEs and
1 companion diagnostic: (1) CapoxigemŽ (apricoxib, TG01) for
the treatment of solid tumors and inflammation-related disorders;
(2) TG02 multi-kinase (FLT3, CDK, JAK2, ERK5) inhibitor for
hematologic and solid tumor malignancies; (3) TG03, a combination
product of Capoxigem and an EGFR-TKI; and, ProGEM, our proprietary
diagnostic being developed as a companion to Capoxigem and
TG03 designed to execute our personalized medicine strategy.
|
